Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants
Vivos Therapeutics (NASDAQ: VVOS) reported single-site clinical study results for its FDA-cleared Vida oral appliance in 37 adults with moderate-to-severe insomnia. All participants improved at least one Insomnia Severity Index category; average ISI fell ~65% and all ended as no clinically significant or subthreshold insomnia (p~1e-7). Vivos cites potential market expansion beyond OSA/COMISA.
How this was made
The 30-second read
Why it matters
The new insomnia dataset is positioned as a potential expansion of Vida’s use into a large underserved insomnia market, which could support higher expectations for recurring appliance sales and service revenues if validated.
Market read
Traders may re-rate VVOS on the prospect of label/indication expansion and a larger addressable market, but should weigh study limitations and lack of regulatory next steps.
What to watch
The article does not provide control/comparator data, effect durability beyond ~3.7 months average wear, adverse events details, or any FDA label expansion timeline for insomnia—key items traders may require before repricing revenue expectations.
Background
Vivos’ Vida oral appliance is already FDA-cleared as a Class II device for TMJ disorders, migraine reduction, and nasal airway dilation; this PR adds insomnia severity outcomes from a small clinical study.
Ticker impact
Vivos reports a single-site study where its FDA-cleared Vida oral appliance improved Insomnia Severity Index in all 37 participants.
Near-term upside bias possible on clinical-data optimism, but magnitude likely tempered by small, single-site sample and need for validation.
The article discloses a new clinical dataset (all participants improved; p-value ~1e-7) and frames it as a potential new revenue driver, which can move sentiment. However, it provides no revenue guidance, no multicenter confirmation, and no regulatory pathway update for insomnia, limiting conviction.
Market effects
If validated, non-pharmacologic oral appliance approaches could gain attention in insomnia/COMISA treatment pathways, potentially increasing competitive focus on device-based sleep therapeutics.
No specific regional market impact beyond Vivos’ referenced Sleep Centers of Nevada patient flow.
The company frames insomnia as a large global market and positions Vida for broader international commercial opportunity if future studies corroborate.
Counterpoint
All-participants improvement in a small, single-site study may overstate efficacy; without multicenter replication and safety/long-term durability data, the market may discount the commercial impact.
Key entities
- CompanyVivos Therapeutics, Inc.
NASDAQ-listed medical device and healthcare services company marketing the Vida oral appliance.
- ProductVida® oral appliance
FDA-cleared Class II oral appliance; PR claims statistically significant insomnia severity improvement in all study participants.
- Clinical metricInsomnia Severity Index (ISI)
Validated instrument used to quantify insomnia symptoms and functional impact; study reports ~65% average ISI reduction.
